Name: 글로벌 시장 동향
SKU: PH7239
Availability: InStock

보고서 요약(국문)

개요
전 세계 알코올성 간염 치료 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
알코올성 간염은 규칙적인 과도한 알코올 섭취로 인해 발생하는 염증성 간 질환입니다. 과도한 알코올 섭취는 간세포를 손상시켜 간의 염증과 흉터를 유발할 수 있습니다. 이 질환은 경증에서 중증까지 다양하게 나타납니다. 중증 알코올성 간염의 경우, 조기에 치료를 받거나 음주를 중단하지 않으면 간 이식이 필요할 수 있습니다.
알코올성 간염의 최적 치료법은 프레드니솔론과 같은 코르티코스테로이드를 사용하여 염증을 줄이는 데 중점을 두고 있으며, 경우에 따라 N-아세틸시스테인이나 면역억제제와 병용 투여할 수 있습니다. 현재까지는 단기적인 생존율 향상만 기대할 수 있으며, 3개월 이상 환자의 생존율을 개선하는 치료법은 아직 발견되지 않았습니다. 장기적인 생존을 위해서는 금주가 매우 중요합니다.
시장 동향: 동인 및 제약 요인
알코올 관련 간 질환의 증가
알코올 관련 간 질환의 증가 추세는 예측 기간 동안 세계 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, BioMed Central Ltd 저널에 2023년에 발표된 금속 분석 논문에 따르면 2022년 전 세계 알코올 관련 간 질환 유병률은 4.8%였습니다. 남성의 유병률은 2.9%로 여성(0.5%)보다 높았습니다. 마찬가지로, 미국 국립보건원(NIH)에 따르면 미국에서 알코올은 간 질환의 주요 원인입니다. 미국 인구의 61% 이상이 알코올 관련 간 질환을 앓고 있으며, 이 중 약 10~12%는 과음자입니다. 또한, 매년 약 88,000명이 알코올 관련 질병으로 고통받고 있으며, 알코올은 미국에서 예방 가능한 사망 원인 중 네 번째로 꼽힙니다.
더욱이, 알코올 관련 질병에 대한 인식 증가, 시장 개발, 연구 투자 및 활동 증가는 예측 기간 동안 세계 시장 성장을 견인할 것으로 예상됩니다.
엄격한 규제 당국
약물 치료를 승인하는 엄격한 규제 당국은 세계 시장 성장을 저해할 것으로 예상됩니다. 또한, 높은 약물 개발 비용과 치료 부작용 또한 예측 기간 동안 세계 시장 성장을 저해할 것으로 예상됩니다.
세분화 분석
세계 알코올성 간염 치료 시장은 약물 유형, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
단클론 항체 약물 유형, 시장 주도 예상
간 질환에 대한 단클론 항체 약물 유형 치료의 임상 연구가 증가함에 따라 이 부문은 세계 시장에서 큰 비중을 차지할 것으로 예상됩니다. 예를 들어, 2023년 2월 임페리얼 칼리지 런던은 카나키누맙 150mg/ml 주사액에 대한 2상 임상 연구 시작을 발표했습니다. ISAIAH 연구의 직접적인 목적은 알코올성 간염 치료에 IL-1β 항체인 카나키누맙(주사액)을 사용하는 것의 잠재적 이점을 조사하는 것입니다.
또한, 질병 재발 위험이 높은 초기 간세포암(HCC) 환자를 대상으로 아테졸리주맙(테센트릭, 제넨텍)과 베바시주맙(아바스틴, 제넨텍) 병용 요법을 연구한 핵심 3상 IMbrave050 임상시험의 최근 결과에 따르면, 이 연구는 무재발 생존(RFS)이라는 직접적인 평가변수를 충족했습니다. 또한, 간세포암(HCC) 환자 10명 중 9명은 알코올성 간질환, 만성 B형 및 C형 간염, 비알코올성 지방간 질환, 비알코올성 지방간염, 그리고 이러한 질환으로 인한 간경변증과 같은 만성 간질환으로 인해 발생합니다.
지리적 분석
북미, 세계 시장 주도 예상
북미 주요 기업들의 승인 증가와 연구 활동 확대는 북미 지역 시장의 성장을 촉진하고 세계 시장을 주도할 것으로 예상됩니다. 예를 들어, 2023년 8월, 오션(Ocean)의 소분자 후보 물질은 여러 시험 기준에서 특발성 폐섬유증(IPF)과 헤르만스키-푸들락 증후군(HPS)의 섬유화 진행을 억제하는 것으로 나타났으며, IPF, HPS, 알코올성 간질환, 비알코올성 지방간염(NASH), 그리고 경피증 치료에 대한 특허를 획득했습니다.

또한, 2022년 11월, 미국의 바이오제약 회사인 인터셉트 파마슈티컬스(Intercept Pharmaceuticals, Inc.)는 중증 알코올성 간염(sAH) 치료를 위한 차세대 FXR 작용제인 INT-787 개발에 집중하고 있다고 발표했습니다. 알코올성 간질환은 현재 미국에서 간 이식 대기자 명단에 오르는 가장 흔한 질환이며, 특히 sAH로 인해 간 이식이 필요한 환자가 크게 증가하고 있습니다. 현재 sAH 치료를 위해 승인된 약물은 없습니다.
코로나19 영향 분석
수많은 연구에서 코로나19 팬데믹으로 인해 과음이 증가하고 알코올성 간질환(ARLD) 환자가 늘어났으며, 특히 여성에게 불균형적인 영향을 미쳤다고 지적했습니다. 2020년 알코올 관련 사망자는 전체 사망자보다 25% 증가했으며, 알코올성 간질환으로 인한 사망자는 22% 증가했습니다.

더욱이, 영국 정부에 따르면 2021 회계연도에 알코올성 간 질환으로 인한 병원 방문율은 인구 10만 명당 45.5명으로 최고치를 기록했으며, 이는 2011 회계연도 이후 가장 높은 수치로, 2020 회계연도에 비해 훨씬 높은 수치입니다. 최근 Liver International에 발표된 분석에서 헨리 포드 헬스 시스템(Henry Ford Health System) 연구진은 코로나19 팬데믹 초기 몇 달 동안 알코올성 간염으로 입원한 환자 수가 무려 50%나 증가했음을 밝혀냈습니다. 이처럼 간염을 포함한 알코올 관련 간 질환 환자 수의 증가는 치료 수요 증가로 이어져 세계 시장에 긍정적인 영향을 미치고 있습니다.
주요 개발 사항
• 2023년 6월, 급성 장기 손상 및 만성 간 질환 치료를 위한 후성유전학적 치료법을 개발하는 바이오제약 회사인 DURECT Corporation은 중증 알코올 관련 간염(AH) 환자 치료를 위한 라르수코스테롤의 임상 2b상 AHFIRM 연구(NCT04563026)의 환자 등록을 완료하여 등록 목표인 300명을 달성했습니다.

• 2023년 5월, 혁신적인 키나제 억제제를 개발하는 임상 단계 회사인 Seal Rock Therapeutics, Inc.는 급성 간 질환(급성 만성 간부전(ACLF) 포함) 치료를 위한 SRT-015 주사제 개발을 위해 GENFIT과 라이선스 계약을 체결했습니다.

• 2022년 12월, Aldeyra Therapeutics, Inc.는 최초의 경구 투여형 신약 후보 물질인 ADX-629에 대한 순차 무작위 배정, 이중 맹검, 위약 대조 교차 2상 임상 연구에서 알코올 중독 적응증에 대한 표적 효과 및 진전을 입증했습니다.

경쟁 환경
시장의 주요 글로벌 업체로는 Sanofi, Lupin Limited, Genentech, Inc., Teva Pharmaceutical Industries Limited, Pfizer Inc., Alkermes Public Limited Company, Torrent Pharmaceuticals Limited, Wellona Pharma, Viatris Inc. 등이 있습니다.
보고서 구매 이유

• 약물 유형, 투여 경로, 유통 채널 및 지역별 글로벌 알코올성 간염 치료 시장 세분화를 시각화하고 주요 상업적 자산 및 업체를 파악하기 위해

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별하기 위해

• 모든 세그먼트를 포함한 알코올성 간염 치료 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트 제공

• PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 자료로 구성됩니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료는 엑셀 파일로 제공됩니다.
글로벌 알코올성 간염 치료 시장 보고서는 약 61개의 표, 59개의 그림, 186페이지 분량입니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Alcoholic Hepatitis Treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Alcoholic hepatitis is an inflammatory liver disorder that is induced by regular increased alcohol consumption. Processing extensive quantities of alcohol can impair liver cells, leading to swelling and scarring of the liver. The condition varies from mild or severe. In severe alcoholic hepatitis cases, an individual may need a liver transplant if they do not obtain treatment or do not cease drinking alcohol in the premature phases.
The optimal therapy of alcoholic hepatitis concentrates on decreasing inflammation via the usage of glucocorticoids such as prednisolone, perhaps in combination with N-acetyl cysteine or additional drugs that subdue the immune system. Currently, only short-term gains in survival can be anticipated no therapy has been encountered to improve patient survival past 3 months. Alcohol abstinence is crucial for long-term survival.
Market Dynamics: Drivers & Restraints
Growing Prevalence of Alcohol-Related Liver Diseases
The growing prevalence of alcohol-related liver diseases is expected to boost the global market growth during the forecast period. For instance, according to the BioMed Central Ltd Journal 2023, published metal analysis article conclusion the preponderance of alcohol-related liver disease worldwide in 2022 was 4.8%. The preponderance in men was 2.9%, which was more elevated than female (0.5%). Similarly, according to the NIH, in the United States, alcohol is the top reason for liver disease. It affects over 61% of the American population, and out of the 61%, about 10% to 12% are heavy drinkers. Moreover, around 88,000 individuals are affected with alcohol-related diseases yearly, making alcohol the fourth top preventable reason for death in the U.S.
Furthermore, the growing awareness about alcohol related diseases, market developments, increase in research investments and activities are also driving the global market growth during the forecast period.
Stringent Regulatory Authorities
The stringent regulatory authorities authorizing the drug treatments are expected to hamper the global market growth. Furthermore, high drug development costs and treatment side effects are also expected to hamper the global market growth in the forecast period.
Segment Analysis
The global alcoholic hepatitis treatment market is segmented based on drug type, route of administration, distribution channel and region.
Monoclonal Antibody Drug Type Expected to Dominate Market
Owing to the increase in monoclonal antibody drug-type treatment clinical investigations in liver diseases the segment is estimated to hold a large share of the global market. For instance, in February 2023, Imperial College London reported the beginning of a study of phase 2 clinical investigation for Canakinumab 150mg/ml solution for injection. The immediate purpose of the ISAIAH investigation is to examine the probable benefits of utilizing the IL-1β antibody, Canakinumab (injection solution), for treating alcoholic hepatitis.
Moreover, recent conclusions from the pivotal phase 3 IMbrave050 trial examining atezolizumab (Tecentriq, Genentech) plus bevacizumab (Avastin, Genentech) in patients with early-stage hepatocellular carcinoma (HCC) at elevated threat of disease recurrence has encountered that the investigation fulfilled its immediate endpoint of recurrence-free survival (RFS). Also, 9 out of 10 patients of HCC are induced by chronic liver condition, such as includes alcohol-related liver disease, chronic hepatitis B and C infection, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and cirrhosis resulting from these disorders.
Geographical Analysis
North America is Expected to Dominate the Global Market
The increasing approvals and growing research activities of North America based key players are expected to boost the regional market growth dominating the global market. For instance, in August, 2023, Ocean’s small molecule nominee particularly prevents fibrosis advancement in idiopathic pulmonary fibrosis (IPF) and Hermansky-Pudlak Syndrome (HPS) in multiple testing standards, it was also granted patent for usage in IPF, HPS, alcoholic liver condition, nonalcoholic steatohepatitis (NASH), and scleroderma.
Moreover, in November, 2022, Intercept Pharmaceuticals, Inc. is an American biopharmaceutical corporation reported its strategies concentrated in designing its next-generation FXR agonist, INT-787, in severe alcohol-associated hepatitis (sAH). Alcohol-related liver disease is presently the top indication for liver transplant listing in the U.S., with a significant growth in patients with sAH requiring liver transplantation. Presently, there are no drugs with an authorized indication for the treatment of sAH.
COVID-19 Impact Analysis
Bunches of analysis have connected the pandemic to an upsurge in heavy drinking and a growth in alcohol-related liver disease (ARLD), with a disproportionate effect on females. Total casualties concerning alcohol grew 25% in 2020, with a 22% growth in alcohol-associated liver disorder casualties.
Moreover, according to the UK government rates of visits to hospitals for the alcoholic liver condition in the financial year ending 2021 stood at the highest at 45.5 per 100,000 population, a total of 24,544 admissions they have been since the financial year completing 2011, and are extremely more elevated compared to in the financial year ending 2020. In a recent analysis publicized in Liver International, investigators at Henry Ford Health System have uncovered that individuals hospitalized for alcoholic hepatitis rose a staggering 50% in the early months of the COVID-19 pandemic. Thus, the rise in the number of patients with alcohol-related liver diseases including hepatitis has led to an increase in the demand for the treatment positively impacting the global market.
Key Developments
• In June 2023, DURECT Corporation, a biopharmaceutical corporation designing epigenetic treatments for the treatment of acute organ injuries and chronic liver conditions, finished enrollment in its Phase 2b AHFIRM clinical investigation (NCT04563026) examining larsucosterol for the treatment of individuals with extreme alcohol-associated hepatitis (AH), reaching its registration target of 300 patients.
• In May 2023, Seal Rock Therapeutics, Inc., a clinical-stage corporation designing first-in-class and best-in-class kinase inhibitors, formed an out-licensing deal with GENFIT for the development of an injectable formulation of SRT-015 for an acute liver condition, including Acute-on-Chronic Liver Failure (ACLF).
• In December 2022, Aldeyra Therapeutics, Inc. demonstrated target attention and advancement in the indications of alcohol intoxication in a sequence-randomized, double-masked, placebo-controlled crossover Phase 2 clinical investigation of ADX-629, a first-in-class orally administered investigational unique medicine nominee.
Competitive Landscape
The major global players in the market include Sanofi, Lupin Limited, Genentech, Inc., Teva Pharmaceutical Industries Limited, Pfizer Inc., Alkermes Public Limited Company, Torrent Pharmaceuticals Limited, Wellona Pharma, And Viatris Inc. among others.
Why Purchase the Report?
• To visualize the global alcoholic hepatitis treatment market segmentation based on drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of alcoholic hepatitis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global alcoholic hepatitis treatment market report would provide approximately 61 tables, 59 figures and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug type
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing Prevalence of Alcohol-Related Liver Diseases
4.1.1.2. Increase in Research Investments and Activities
4.1.2. Restraints
4.1.2.1. Stringent Regulatory Authorities
4.1.2.2. High Drug Development Cost
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. Pipeline Analysis
5.8. PEST Analysis
5.9. SWOT Analysis
5.10. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Monoclonal Antibodies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Corticosteroids
7.4. Anabolic Steroids
7.5. Sulfhydryl Drugs
7.6. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Injectable*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Oral
8.4. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Sanofi*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Lupin Limited
12.3. Genentech, Inc.
12.4. Teva Pharmaceutical Industries Limited
12.5. Pfizer Inc.
12.6. Alkermes Public Limited Company
12.7. Torrent Pharmaceuticals Limited
12.8. Wellona Pharma
12.9. Viatris Inc.
12.10. Intercept Pharmaceuticals, Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Sanofi, 4. Key Developments, Lupin Limited, Genentech, Inc., Teva Pharmaceutical Industries Limited, Pfizer Inc., Alkermes Public Limited Company, Torrent Pharmaceuticals Limited, Wellona Pharma, Viatris Inc., Intercept Pharmaceuticals, Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Alcoholic Hepatitis Treatment Market Value, By Drug type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Alcoholic Hepatitis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Alcoholic Hepatitis Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Alcoholic Hepatitis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Alcoholic Hepatitis Treatment Market Value, By Drug type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Alcoholic Hepatitis Treatment Market Value, By Drug type, 2021-2030 (US$ Million)

Table 7 Global Alcoholic Hepatitis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Alcoholic Hepatitis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Alcoholic Hepatitis Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Alcoholic Hepatitis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 11 Global Alcoholic Hepatitis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Alcoholic Hepatitis Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Alcoholic Hepatitis Treatment Market Value, By Drug type, 2021-2030 (US$ Million)

Table 14 North America Alcoholic Hepatitis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Alcoholic Hepatitis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 16 North America Alcoholic Hepatitis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Alcoholic Hepatitis Treatment Market Value, By Drug type, 2021-2030 (US$ Million)

Table 18 South America Alcoholic Hepatitis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Alcoholic Hepatitis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 South America Alcoholic Hepatitis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Alcoholic Hepatitis Treatment Market Value, By Drug type, 2021-2030 (US$ Million)

Table 22 Europe Alcoholic Hepatitis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Alcoholic Hepatitis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 Europe Alcoholic Hepatitis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Alcoholic Hepatitis Treatment Market Value, By Drug type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Alcoholic Hepatitis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Alcoholic Hepatitis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Alcoholic Hepatitis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Alcoholic Hepatitis Treatment Market Value, By Drug type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Alcoholic Hepatitis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Alcoholic Hepatitis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 32 Allergan Inc.: Overview

Table 33 Allergan Inc.: Product Portfolio

Table 34 Allergan Inc.: Key Developments

Table 35 Lupin Limited: Overview

Table 36 Lupin Limited: Product Portfolio

Table 37 Lupin Limited: Key Developments

Table 38 Genentech, Inc.: Overview

Table 39 Genentech, Inc.: Product Portfolio

Table 40 Genentech, Inc.: Key Developments

Table 41 Teva Pharmaceutical Industries Limited: Overview

Table 42 Teva Pharmaceutical Industries Limited: Product Portfolio

Table 43 Teva Pharmaceutical Industries Limited: Key Developments

Table 44 Pfizer Inc.: Overview

Table 45 Pfizer Inc.: Product Portfolio

Table 46 Pfizer Inc.: Key Developments

Table 47 Alkermes Public Limited Company: Overview

Table 48 Alkermes Public Limited Company: Product Portfolio

Table 49 Alkermes Public Limited Company: Key Developments

Table 50 Torrent Pharmaceuticals Limited: Overview

Table 51 Torrent Pharmaceuticals Limited: Product Portfolio

Table 52 Torrent Pharmaceuticals Limited: Key Developments

Table 53 Wellona Pharma: Overview

Table 54 Wellona Pharma: Product Portfolio

Table 55 Wellona Pharma: Key Developments

Table 56 Viatris Inc.: Overview

Table 57 Viatris Inc.: Product Portfolio

Table 58 Viatris Inc.: Key Developments

Table 59 Intercept Pharmaceuticals, Inc.: Overview

Table 60 Intercept Pharmaceuticals, Inc.: Product Portfolio

Table 61 Intercept Pharmaceuticals, Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Alcoholic Hepatitis Treatment Market Share, By Drug type, 2022 & 2030 (%)

Figure 3 Global Alcoholic Hepatitis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Alcoholic Hepatitis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Alcoholic Hepatitis Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Alcoholic Hepatitis Treatment Market Y-o-Y Growth, By Drug type, 2022-2030 (%)

Figure 7 Monoclonal Antibodies Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 8 Corticosteroids Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Anabolic Steroids Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Sulfhydryl Drugs Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Others Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Global Alcoholic Hepatitis Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 13 Injectable Route of Administration in Global Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Oral Route of Administration in Global Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 15 Global Alcoholic Hepatitis Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 16 Hospital Pharmacies Distribution Channel in Global Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 17 Retail Pharmacies Distribution Channel in Global Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 18 Online Pharmacies Distribution Channel in Global Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 Others Distribution Channel in Global Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Global Alcoholic Hepatitis Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 21 North America Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 Asia-Pacific Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 23 Europe Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 South America Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 25 Middle East and Africa Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 26 North America Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 27 North America Alcoholic Hepatitis Treatment Market Share, By Drug type, 2022 & 2030 (%)

Figure 28 North America Alcoholic Hepatitis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 29 North America Alcoholic Hepatitis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 30 North America Alcoholic Hepatitis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 31 South America Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 32 South America Alcoholic Hepatitis Treatment Market Share, By Drug type, 2022 & 2030 (%)

Figure 33 South America Alcoholic Hepatitis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 34 South America Alcoholic Hepatitis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 35 South America Alcoholic Hepatitis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 36 Europe Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 37 Europe Alcoholic Hepatitis Treatment Market Share, By Drug type, 2022 & 2030 (%)

Figure 38 Europe Alcoholic Hepatitis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 39 Europe Alcoholic Hepatitis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 40 Europe Alcoholic Hepatitis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 41 Asia-Pacific Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 42 Asia-Pacific Alcoholic Hepatitis Treatment Market Share, By Drug type, 2022 & 2030 (%)

Figure 43 Asia-Pacific Alcoholic Hepatitis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 44 Asia-Pacific Alcoholic Hepatitis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 45 Asia-Pacific Alcoholic Hepatitis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 46 Middle East & Africa Alcoholic Hepatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 47 Middle East & Africa Alcoholic Hepatitis Treatment Market Share, By Drug type, 2022 & 2030 (%)

Figure 48 Middle East & Africa Alcoholic Hepatitis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 49 Middle East & Africa Alcoholic Hepatitis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 50 Allergan Inc.: Financials

Figure 51 Lupin Limited: Financials

Figure 52 Genentech, Inc.: Financials

Figure 53 Teva Pharmaceutical Industries Limited: Financials

Figure 54 Pfizer Inc.: Financials

Figure 55 Alkermes Public Limited Company: Financials

Figure 56 Torrent Pharmaceuticals Limited: Financials

Figure 57 Wellona Pharma: Financials

Figure 58 Viatris Inc.: Financials

Figure 59 Intercept Pharmaceuticals, Inc.: Financials

세계 알코올성 간염 치료 시장 – 2023-2030

Global Alcoholic Hepatitis Treatment Market -2023-2030